Although our data and that from other pre-clinical studies [23] show promising results on the use of NADD and other vanilloid receptor related agonists in AKI, further studies are warranted to address the underlying renoprotective mechanism including the role of the capsaicin receptor TRPV1. This evidence concerns the gene TRPV1 and acute kidney injury.